Acquisition of Acrivon Therapeutics, Inc. Common Stock by RA Capital Management, L.P.

RA Capital Management, L.P. and its affiliated entities reported a transaction involving Acrivon Therapeutics, Inc. common stock. On May 18, 2026, RA Capital Management, L.P. acquired 9,366 shares of common stock through a restricted stock unit (RSU) award to Dr. Derek DiRocco, a partner at the Adviser and a member of Acrivon Therapeutics, Inc.'s board of directors. The RSUs vest on March 18, 2027, contingent upon Dr. DiRocco's continued service. These RSUs are held for the benefit of RA Capital Healthcare Fund LP and RA Capital Nexus Fund II, L.P., and any stock received upon settlement will offset advisory fees. Consequently, the reporting persons disclaim beneficial ownership of these RSUs and the underlying shares, except to the extent of any pecuniary interest. Following this transaction, RA Capital Healthcare Fund LP holds 11,803,094 shares, and RA Capital Nexus Fund II, L.P. holds 426,302 shares, with both holdings subject to footnotes detailing ownership nature.